For example, the extension of indication for crizotinib to include treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) was supported by results from a single-arm trial, considering the high response rate observed and that ROS1-positive NSCLC represents a rare, serious and life-threatening distinct molecular subset (11). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.